close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.220 +0.190 (+3.78%)
Streaming Delayed Price Updated: 3:14 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 Next >
News headline image
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Launches Pancreatic Cancer Advisory Board
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
News headline image
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
News headline image
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
News headline image
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Former Chairman, CEO and Founder of ChemoCentryx, Inc. 
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces Participation in February Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today